Black Rock Inc. Aligos Therapeutics, Inc. Transaction History

Black Rock Inc.

$4.23 Trillion
Q1 2024

A detailed history of Black Rock Inc. transactions in Aligos Therapeutics, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 303,755 shares of ALGS stock, worth $209,590. This represents 0.0% of its overall portfolio holdings.

Number of Shares

303,755

Previous 296,139 2.57%

Holding current value

$209,590

Previous $195,000 52.31%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$0.64 - $1.13 $4,874 - $8,606	7,616 Added 2.57%	303,755 $297,000
Q4 2023 Feb 13, 2024	SELL	$0.56 - $0.8 $459 - $656	-820 Reduced 0.28%	296,139 $195,000
Q3 2023 Nov 13, 2023	SELL	$0.71 - $1.06 $2,487 - $3,714	-3,504 Reduced 1.17%	296,959 $222,000
Q2 2023 Aug 11, 2023	SELL	$0.89 - $1.36 $6,352 - $9,707	-7,138 Reduced 2.32%	300,463 $291,000
Q1 2023 May 12, 2023	BUY	$0.87 - $2.11 $132 - $320	152 Added 0.05%	307,601 $267,000

Q4 2022 Feb 13, 2023	SELL	$0.89 - $1.08 $186,997 - $226,918	-210,110 Reduced 40.6%	307,449 $292,000
Q3 2022 Nov 14, 2022	SELL	$1.06 - $1.6 $8,476 - $12,795	-7,997 Reduced 1.52%	517,559 $569,000
Q2 2022 Aug 12, 2022	SELL	$1.04 - $2.14 $1.12 Million - $2.3 Million	-1,075,462 Reduced 67.17%	525,556 $636,000
Q1 2022 May 12, 2022	BUY	$2.08 - $12.2 $5,647 - $33,123	2,715 Added 0.17%	1,601,018 $3.44 Million
Q4 2021 Feb 10, 2022	BUY	$11.48 - $17.69 $4.12 Million - $6.35 Million	358,741 Added 28.94%	1,598,303 $19 Million
Q3 2021 Nov 09, 2021	BUY	$14.57 - $17.72 $2.27 Million - $2.76 Million	155,518 Added 14.35%	1,239,562 $19.2 Million
Q2 2021 Aug 11, 2021	BUY	$20.3 - $33.6 $22 Million - $36.4 Million	1,084,044 New	1,084,044 $22.1 Million

Others Institutions Holding ALGS

# of Institutions

Shares Held

46.2M

Call Options Held

6.11M

Put Options Held

200

View Full List

About Aligos Therapeutics, Inc.

Ticker ALGS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,717,000
Market Cap $27.4M
Description
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB);...

More about ALGS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account